Beverly Hills Beauty Blog

Pharmawire Reports on Botox Cosmetic Trends, Dr. Assassa Is Expert Source

July 14th, 2008

Pharmawire is a news wire service dedicated to reporting the latest news in the pharmaceutical industry. Beverly Hills Aesthetics’ Dr. Assassa was featured on Pharmawire to lend his expert opinion to the discussion on Allergan’s Botox Cosmetic and its newest competitor Medicis’ Phase III Reloxin.

Pharmawire’s feature on Botox discussed the growth potential in the cosmetic market, despite recent economic downturns. It explained that while individuals who have never used Botox might delay initiating introductory appointments but those who are already using fillers will continue to do so.

Dr. Assassa agreed with this assessment, stating that patients are extending the time between injections, but not forgoing them entirely.

Dr. Assassa added to this by stating, “It would be nice to see the [Botox] monopoly broken up. I think it will be good for the consumer.”

Additionally, with the negative rumours surrounding Botox usage, one can help but wonder if this effects patient’s decisions to continue their treatments.

Dr. Assassa gives his opinion stating, “It’s something that’s an eye-opener, but nothing to be concerned about at this point. Botox has been around in this country since 1989. If there’s any safety issue, I think it becomes negligible. It’s a drop of water in the ocean.”

It is important to recognize that each of these products, Botox and Reloxin have their individual benefits and that the physician will choose which product is best fit for each patient, depending on their needs. While Reloxin consists of the same botulinum type A toxin used in Botox, Reloxin will be packaged differently and have differences in purification and dilution.

For further information on Botox and fillers visit www.bhaesthetics.com.

Entry Filed under: Beverly Hills Cosmetic Services, Cosmetic Surgery Services, Dr. Sam Assassa